• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 5. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere

(1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol (CAS No. 1932441-50-3): An Overview of a Promising Compound in Chemical and Pharmaceutical Research

(1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol (CAS No. 1932441-50-3) is a chiral compound that has garnered significant attention in the fields of chemical and pharmaceutical research due to its unique structural properties and potential applications. This compound, characterized by its 3-bromopyridin-4-yl and ethanol moieties, exhibits a range of biological activities that make it a valuable candidate for further investigation.

The chiral center at the carbon atom adjacent to the hydroxyl group in (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol is a key feature that influences its reactivity and selectivity in various chemical reactions. Chirality plays a crucial role in drug design and development, as enantiomers can exhibit different pharmacological properties, toxicity profiles, and metabolic pathways. The ability to synthesize and isolate specific enantiomers is essential for optimizing the therapeutic potential of compounds like (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol.

In recent studies, (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol has shown promising results in various biological assays. For instance, it has demonstrated significant activity against certain bacterial strains, making it a potential lead compound for the development of new antibiotics. The bromine atom in the pyridine ring contributes to the compound's ability to interact with specific biological targets, such as enzymes and receptors involved in bacterial metabolism.

Beyond its antibacterial properties, (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol has also been investigated for its potential as an anticancer agent. Preliminary studies have shown that this compound can induce apoptosis in cancer cells by disrupting key signaling pathways. The mechanism of action involves the modulation of protein kinases and other cellular proteins that are critical for cell survival and proliferation. These findings suggest that (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol could be further developed as a novel therapeutic agent for cancer treatment.

The synthesis of (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol typically involves multi-step processes that require precise control over reaction conditions to ensure high yields and enantiomeric purity. One common approach involves the reaction of 3-bromopyridine with an appropriate chiral auxiliary followed by reduction and subsequent deprotection steps. Advances in asymmetric synthesis techniques have greatly improved the efficiency and scalability of these processes, making it feasible to produce large quantities of this compound for further research and development.

In addition to its therapeutic potential, (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol has also been explored as a building block for the synthesis of more complex molecules. Its versatile reactivity allows it to be incorporated into a wide range of organic frameworks, enabling the creation of novel compounds with diverse biological activities. This makes it a valuable intermediate in the development of new drugs and materials.

The safety profile of (1S)-1-(3-Bromopyridin-4-yl)ethan-1-ol is another important consideration in its evaluation as a potential therapeutic agent. Preclinical studies have shown that this compound exhibits low toxicity at effective concentrations, which is a favorable attribute for drug candidates. However, further investigations are necessary to fully understand its pharmacokinetics, metabolism, and long-term effects in vivo.

In conclusion, (1S)-1-(3-Bromopyridin-4-y l)ethan - 1 - ol (CAS No . 193244 1 - 50 - 3) strong > represents a promising compound with diverse applications in chemical and pharmaceutical research. Its unique structural features, biological activities, and synthetic accessibility make it an attractive candidate for further exploration and development. As research in this area continues to advance, it is likely that new insights into the properties and potential uses of this compound will emerge, contributing to the advancement of both fundamental science and practical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)